Lymphangioleiomyomatosis as a potent lung cancer risk factor: Insights from a Japanese large cohort study
- PMID: 38654512
- DOI: 10.1111/resp.14724
Lymphangioleiomyomatosis as a potent lung cancer risk factor: Insights from a Japanese large cohort study
Abstract
Background and objective: Lymphangioleiomyomatosis (LAM) is a rare neoplastic disease associated with the functional tumour suppressor genes TSC1 and TSC2 and causes structural destruction in the lungs, which could potentially increase the risk of lung cancer. However, this relationship remains unclear because of the rarity of the disease.
Methods: We investigated the relative risk of developing lung cancer among patients diagnosed with LAM between 2001 and 2022 at a single high-volume centre in Japan, using data from the Japanese Cancer Registry as the reference population. Next-generation sequencing (NGS) was performed in cases where tumour samples were available.
Results: Among 642 patients diagnosed with LAM (sporadic LAM, n = 557; tuberous sclerosis complex-LAM, n = 80; unclassified, n = 5), 13 (2.2%) were diagnosed with lung cancer during a median follow-up period of 5.13 years. All patients were female, 61.5% were never smokers, and the median age at lung cancer diagnosis was 53 years. Eight patients developed lung cancer after LAM diagnosis. The estimated incidence of lung cancer was 301.4 cases per 100,000 person-years, and the standardized incidence ratio was 13.6 (95% confidence interval, 6.2-21.0; p = 0.0008). Actionable genetic alterations were identified in 38.5% of the patients (EGFR: 3, ALK: 1 and ERBB2: 1). No findings suggested loss of TSC gene function in the two patients analysed by NGS.
Conclusion: Our study revealed that patients diagnosed with LAM had a significantly increased risk of lung cancer. Further research is warranted to clarify the carcinogenesis of lung cancer in patients with LAM.
Keywords: TSC1; TSC2; lung cancer; lymphangioleiomyomatosis; rare lung diseases; tumour suppressor gene.
© 2024 Asian Pacific Society of Respirology.
References
REFERENCES
-
- McCormack FX, Gupta N, Finlay GR, Young LR, Taveira‐DaSilva AM, Glasgow CG, et al. Official American Thoracic Society/Japanese Respiratory Society Clinical Practice Guidelines: Lymphangioleiomyomatosis diagnosis and management. Am J Respir Crit Care Med. 2016 Sep 15;194(6):748–761.
-
- Johnson SR, Cordier JF, Lazor R, Cottin V, Costabel U, Harari S, et al. European Respiratory Society guidelines for the diagnosis and management of lymphangioleiomyomatosis. Eur Respir J. 2010 Jan 1;35(1):14–26.
-
- Harknett EC, Chang WYC, Byrnes S, Johnson J, Lazor R, Cohen MM, et al. Use of variability in national and regional data to estimate the prevalence of lymphangioleiomyomatosis. QJM Int J Med. 2011 Nov;104(11):971–979.
-
- Dang NV, Son LX, Hong NTT, Nhung NTT, Tung NT, Quang LV. Recurrence of carcinoma showing thymus‐like differentiation (CASTLE) involving the thyroid gland. Thyroid Res. 2021 Dec;14(1):20.
-
- Carsillo T, Astrinidis A, Henske EP. Mutations in the tuberous sclerosis complex gene TSC2 are a cause of sporadic pulmonary lymphangioleiomyomatosis. Proc Natl Acad Sci. 2000 May 23;97(11):6085–6090.
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous